Confirmed
One controlled phase 3 trial met its main goal, and natalizumab is approved for this use.
Integrin blockade (lymphocyte trafficking): slow disability worsening in relapsing MS
relapsing MS · Integrin blockade (lymphocyte trafficking)
Two or more controlled phase 3 trials met their main goal, or one did and a medicine of this approach is approved for this use.
- Trials
- 7
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 1200
Deciding trials (phase 3): 1 met, 0 did not.
Other linked trials: 6
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
- Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosisdecides the statusMet main goal
Phase 3 · 2002 · Placebo-controlled · MSFT-NCT00030966
Combination therapy resulted in a 24 percent reduction in the relative risk of sustained disability progression (hazard ratio, 0.76; 95 percent confidence interval, 0.61 to 0.96; P=0.02).
Read by software from the paper's abstract
Other linked trials: 6
These linked trials do not set the status.
- ESCALATEStopped, other reason
Phase 4 · 2014 · Not randomised
- TIMERMet main goal
Phase 4 · 2009 · Not randomised
- TIMERNo result found
Phase 4 · 2009 · Not randomised
- STRATAStopped, other reason
Phase 3 · 2006 · Not randomised
- TREAT-MSResult in a paper, not read yet
Phase not applicable · 2018 · Not randomised
Phase not applicable · 2010 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Status changed from Results pending to Confirmed
- 2026-10-27First listed as Results pending
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error